Skip to main content

Aggrecan 293T Cell Transient Overexpression Lysate, Novus Biologicals

Bio-Techne includes Novus Biologicals | Catalog # H00000176-T01

Catalog #
Availability
Size / Price
Qty
Loading...
H00000176-T01

Key Product Details

Species

Human

Applications

Western Blot

Product Summary for Aggrecan 293T Cell Transient Overexpression Lysate

Quality control test: Transient overexpression cell lysate was tested with Anti-AGC1 antibody by Western Blots. Plasmid: pCMV-AGC1 full-length

Product Specifications

Specificity

AGC1 293T Cell Transient Overexpression Lysate(Denatured)

Type

293T Cell Transient Overexpression

Protein State

Denatured

Formulation, Preparation, and Storage

Formulation

1X Sample Buffer (50 mM Tris-HCl, 2% SDS, 10% glycerol, 300 mM 2-mercaptoethanol, 0.01% Bromophenol blue)

Concentration

Please contact technical services for concentration.

Shipping

The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.

Storage

Store at -80C. Avoid freeze-thaw cycles.

Background: Aggrecan

This aggrecan degradation product usually remains within the tissue still complexed to hyaluronan and link protein. Its release from the cartilage usually signals that there has been extensive catabolism of aggrecan, which allows large complexes containing this metabolite to be released from the tissue.

Alternate Names

ACAN, AGC1, CSPG1, CSPGCP, MSK16, SEDK

Gene Symbol

ACAN

Additional Aggrecan Products

Product Documents for Aggrecan 293T Cell Transient Overexpression Lysate

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Aggrecan 293T Cell Transient Overexpression Lysate

This product is produced by and distributed for Abnova, a company based in Taiwan.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Lysates are guaranteed for 6 months from date of receipt.

Loading...
Loading...
Loading...
Loading...